Short Interest in ABIVAX Société Anonyme (NASDAQ:ABVX) Grows By 19.0%

ABIVAX Société Anonyme (NASDAQ:ABVX) saw a large growth in short interest in December. As of December 15th, there was short interest totalling 577,200 shares, a growth of 19.0% from the November 30th total of 484,900 shares. Currently, 1.1% of the shares of the company are sold short. Based on an average daily volume of 139,700 shares, the short-interest ratio is currently 4.1 days.

Wall Street Analyst Weigh In

ABVX has been the topic of a number of research analyst reports. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. JMP Securities assumed coverage on ABIVAX Société Anonyme in a report on Wednesday, December 4th. They issued an “outperform” rating and a $33.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $38.67.

ABIVAX Société Anonyme Price Performance

Shares of ABVX stock opened at $7.05 on Tuesday. ABIVAX Société Anonyme has a 52-week low of $6.65 and a 52-week high of $17.02. The business has a 50-day simple moving average of $9.06 and a 200-day simple moving average of $10.88.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its stake in shares of ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the period. Walleye Capital LLC raised its position in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after acquiring an additional 80,807 shares during the period. abrdn plc boosted its stake in shares of ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after acquiring an additional 198,225 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock valued at $6,254,000 after acquiring an additional 119,300 shares during the period. Institutional investors and hedge funds own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.